$MRK Intelligence Report
Auto-generated from 10+ sources · Updated hourly
AI Summary
Merck & Co., Inc. Faces Mixed Sentiment Amid Insider Selling and FDA News.
In addition to the insider selling, MRK has been in the news with ten articles published recently. Notably, the company received a priority review designation from the FDA for its new ADC drug targeting lung cancer, which could be a significant growth driver. However, the stock has also faced downward pressure, as indicated by a report stating that MRK's stock price has declined even as the broader market has gained. The mixed signals from news articles and insider trading activity contribute to a complex outlook for the company.
Insider Trades
$2.4M total
News
New Survey Shows HPV Awareness Isn't Keeping Pace with Certain HPV-Related Cancer Trends in Canada
Yahoo
MRK, Daiichi's BLA for ADC Drug Gets FDA Priority Tag in Lung Cancer
Yahoo
Merck (MRK) Stock Sinks As Market Gains: Here's Why
Yahoo
UBS Maintains Buy on Merck & Co, Raises Price Target to $145
Benzinga
Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy
Yahoo
Earnings
No data available
Wikipedia Pageviews
Current: 4/day
Previous: 4/day
Alt Data Pulse
Signal Correlations
1
clusters found
20
events analyzed
Mar 31 — Apr 8 · 8 events · 9 days
2 sources (insider_trade, sec_filing) fired 8 events within 8 days
Build this into your app
Access this data programmatically via our REST API, Python SDK, or JavaScript SDK.
cURL
curl "https://api.gettrawl.com/api/report/MRK"Python
from trawl import Trawl
client = Trawl(api_key="your_key")
report = client.report("MRK")JavaScript
import Trawl from "trawl-sdk";
const trawl = new Trawl({ apiKey: "your_key" });
const report = await trawl.report("MRK");